Healthcare's Health Scanner: Complementary Research on Pfizer, Mylan, Teva Pharmaceutical, Bristol-Myers Squibb, and Merck & Company
22 Apr, 2015, 08:00 ET
NEW YORK, April 22, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Moments ago, Analysts Review released new research updates concerning several important developing situations including Pfizer Inc. (NYSE: PFE), Mylan NV. (NASDAQ: MYL), Teva Pharmaceutical Industries Limited (NYSE: TEVA), Bristol-Myers Squibb Company (NYSE: BMY), and Merck & Company Inc. (NYSE: MRK). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
To access our full PDF reports on a complementary basis, please visit the links below.
Today's update concerns the following companies:
Full PDF Download Links (you may have to copy and paste the following links into your browser):
PFE Research Report: ( http://get.analystsreview.com/pdf/?c=Pfizer%20Inc.&d=22-Apr-2015&s=PFE ),
MYL Research Report: ( http://get.analystsreview.com/pdf/?c=Mylan%20N.V.&d=22-Apr-2015&s=MYL ),
TEVA Research Report: ( http://get.analystsreview.com/pdf/?c=Teva%20Pharmaceutical&d=22-Apr-2015&s=TEVA ),
BMY Research Report: ( http://get.analystsreview.com/pdf/?c=Bristol-Myers%20Squibb&d=22-Apr-2015&s=BMY ),
MRK Research Report: ( http://get.analystsreview.com/pdf/?c=Merck&d=22-Apr-2015&s=MRK ).
Analyst Update: Litigations, Speculated Acquisition, Estimates and Clinical Trials
Reviewed by: Rohit Tuli, CFA®
U.S. stocks mostly closed lower on Tuesday amid a mixed bag of earnings reports. The Dow Jones Industrial Average fell 0.47% to 17949.59, and the S&P 500 ended the session 0.15% lower at 2097.31. On a positive note, the NASDAQ gained 0.39% to close at 5014.10, mainly supported by big gains in biotechnology stocks amid strong M&A activities. European stocks continued their strong run on Tuesday. Major European markets closed the session higher, as Germany's DAX jumped 0.4%; Britain's FTSE 100 rose 0.15%, and France's CAC gained 0.10%. Meanwhile, Asian markets surged on Tuesday, recovering from their disappointing session on the previous day. The Shanghai Composite, Japan's Nikkei and Hong Kong's Hang Seng all posted positive gains.
On April 17, 2015, Pfizer, Inc. (Pfizer) received a verdict from St. Louis court rejecting the claims that Zoloft, an anti-depressant drug, caused birth defects in children born to mothers who took the drug during pregnancy. The jury in the St. Louis, Missouri court dismissed the arguments claiming that Pfizer should pay for damages for heart abnormalities caused by administering the drug to the Plaintiff Kristyn Pesante.
On April 17, 2015, commenting on speculation of a potential bid by Teva for Mylan NV (Mylan), Mylan's Executive Chairman Robert J. Coury dismissed the media speculation as rumor by quoting that Mylan is fully committed to its stand-alone strategy, including its proposal to acquire Perrigo, and today's speculation has no impact whatsoever on this strategy.
Teva Pharmaceutical Industries Ltd. (TEVA) announced that it will release its first quarter 2015 financial results on April 30, 2015 at 7:00 a.m. ET. The results release will be followed by a conference call and live webcast which will be held at 8:00 a.m. ET to discuss the results and overall business environment.
On April 17, 2015, Bristol-Myers Squibb Company announced that CheckMate -057, a Pivotal Phase III Opdivo (nivolumab) Lung Cancer Trial, has been stopped early because an assessment conducted by the independent Data Monitoring Committee (DMC) concluded that the study met its endpoint of overall survival and secondary objectives of response rate and progression free survival.
Merck & Company (Merck) has filed for U.S. Food and Drug Administration (FDA) approval of the drug Keytruda, as a treatment for patients with non-small cell lung cancer (NSCLC) whose disease has worsened despite previous treatment. The trial has shown to shrink tumors in nearly half of advanced lung cancer patients with high levels of a protein used by tumors to evade the body's own disease-fighting cells.
About Analysts Review
At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.
Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
Share this article